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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Flemish language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 100 JIA patients (8% systemic, 33% oligoarticular, 24% RF negative polyarthritis, 35% 
other categories) and 99 healthy children, were enrolled in two centres. The JAMAR components discriminated well healthy 
subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the Flemish 
version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical 
practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Flemish parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the epidemiol-
ogy, outcome and treatment of childhood arthritis (EPOCA) 
in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Flemish language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified accord-
ing to the ILAR criteria [5, 6] and enrolled from December 
2015 to March 2016. Children were recruited after Ethics 
Committee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10];
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. Assessment of morning stiffness (present/absent);
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. Rating of the level of disease activity on a 21-num-
bered circle VAS;
 7. Rating of disease status at the time of the visit (cat-
egorical scale);
 8. Rating of disease course from previous visit (categori-
cal scale);
 9. Checklist of the medications the patient is taking (list 
of choices);
 10. Checklist of side effects of medications;
 11. Report of difficulties with medication administration 
(list of items);
 12. Report of school/university/work problems caused by 
the disease (list of items);
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
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The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal items-scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the 6 JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18]. Test–retest reliability of the Flemish version 
of the JAMAR was not assessed.
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Flemish parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross cultural adaptation
The Flemish JAMAR was cross-culturally adapted from the 
Dutch version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range 90–100%). All the 120 lines of the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range 80–100%). 
The parent and child versions of the Flemish JAMAR were 
unmodified after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 99 healthy children (total of 
199 subjects), were enrolled at two paediatric rheumatology 
centres.
In the 100 JIA subjects, the JIA categories were 8% with 
systemic arthritis, 33% with oligoarthritis, 24% with RF 
negative polyarthritis, 2% with RF positive polyarthritis, 6% 
with psoriatic arthritis, 13% with enthesitis related arthritis 
and 14% with undifferentiated arthritis (Table 1).
A total of 189/199 (95%) subjects had the parent version 
of the JAMAR completed by a parent (90 from parents of 
JIA patients and 99 from parents of healthy children). The 
JAMAR was completed by 163/189 (86.2%) mothers and 
26/189 (13.8%) fathers. The child version of the JAMAR 
was completed by 98/199 (49.2%) children age 6.5 or older. 
Also patients younger than 7 years old, capable to assess 
their personal condition and able to read and write, were 
asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients. In summary, the JAMAR 
revealed that JIA patients had a greater level of disability 
and pain, as well as a lower HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses were 1.1% (0.6–3.3%).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items except items 6, 7, 8 and 10, whereas a reduced 
number of response choices was used for all the PF items 
except items 1, 3, 8 and 10.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown). The median number of items marked as 
not applicable was 1% (0–1%) for the PF and 2.5% (1–4%) 
for the HRQoL.
S190 Rheumatology International (2018) 38 (Suppl 1):S187–S194
1 3
Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 100 JIA patients
Systemic Oligoar-
thritis
RF− Poly-
arthritis
RF + Poly-
arthritis
Psoriatic 
arthritis
Enthesitis 
related 
arthritis
Undif-
ferentiated 
arthritis
All JIA 
patients
Healthy
N = 8 N = 33 N = 24 N = 2 N = 6 N = 13 N = 14 N = 100 N = 99
Female 6 (75%) 30 (90.9%) 18 (75%) 2 (100%) 5 (83.3%) 3 (23.1%) 8 (57.1%) 72 (72%)** 48 (48.5%)**
Age at visit 13.9 (10.4–
14.9)
10.6 
(6–14.7)
10.6 
(6.6–15.1)
13.1 
(8.6–17.6)
14.1 (12.8–
15.2)
15.4 (13.9–
16.2)
11.3 (10.5–
14.2)
12.6 
(8.5–15)*
10.9 
(7.5–14.4)
Age at onset 9.1 (3–14) 3.6 
(1.8–8.7)
5 (1.6–9) 6.1 (5.7–6.5) 11.6 (10.6–
13.8)
12.7 (10.3–
14.1)
3.8 
(1.7–9.6)
6.1 (1.9–
10.7)#
Disease 
duration
3.4 
(0.7–6.5)
3.3 
(1.4–6.5)
4.7 (1.6–7) 7 (2.1–12) 2 (1.2–4.2) 2.8 (1.1–4.8) 7.1 (1–8.7) 3.9 
(1.4–6.7)
ESR 1.9 (1–7) 4 (3–15) 5 (3–8) 2 (2–2) 10 (4–14.5) 2 (1–7) 7 (2–18) 4 (2–9)
MD VAS 
(0–10 cm)
0 (0–1) 0 (0–1) 0.3 (0–2.3) 2 (1–3) 1.8 (0–3.5) 1 (0–2) 2 (0–2.5) 0 (0–2)
No. swollen 
joints
0 (0–0) 0 (0–0) 0 (0–1.5) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–2) 0 (0–0)
No. joints 
with pain
0 (0–0) 0 (0–1) 0 (0–2) 13 (5–21) 1 (0–2) 1 (0–2) 1 (0–3) 0 (0–2)*
No. joints 
with LOM
0 (0–1.5) 0 (0–1) 0 (0–1.5) 6 (1–11) 0 (0–0) 0 (0–1) 0 (0–2) 0 (0–1)
No. active 
joints
0 (0–0) 0 (0–1) 0 (0–2) 5.5 (0–11) 0 (0–0) 0 (0–1) 0 (0–2) 0 (0–1)
Active 
systemic 
features
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (7.1%) 1 (1%)
ANA status 0 (0%) 9 (27.3%) 9 (37.5%) 0 (0%) 1 (16.7%) 0 (0%) 6 (42.9%) 25 (25%)
Uveitis 0 (0%) 8 (24.2%) 5 (20.8%) 0 (0%) 0 (0%) 0 (0%) 2 (14.3%) 15 (15%)
PF Total 
Score
1 (0–1) 0 (0–3) 0.5 (0–3) 3.5 (3–4) 2 (1–5) 0 (0–6) 1.5 (0–10) 1 (0–4) 0 (0–0)#
Pain VAS 0.3 (0–1.5) 0 (0–2.5) 2.3 (0.5–3.5) 6.8 (6–7.5) 3.5 (3–7) 2.5 (0.5–6) 1.5 (0–6.5) 1.3 (0–5) 0 (0–0)#
Disease 
activity 
VAS
0.3 (0–0.5) 0 (0–3.5) 1 (0–4) 5.8 (4–7.5) 3.5 (3–4) 1.5 (0.5–5) 1 (0–5.5) 1 (0–5)
Well-being 
VAS
0.5 (0–1) 0 (0–1) 1.5 (0.5–4) 6.5 (6–7) 5 (3–6.5) 3.5 (0.5–6.5) 1 (0–5) 1 (0–5)*
HRQoL PhH 0.5 (0–3) 1 (0–3) 1 (0–5) 5 (5–5) 7 (2–9) 4 (0–7) 5.5 (0–9) 2 (0–5) 0 (0–0)#
HRQoL PsH 1 (0–2) 0.5 (0–2) 1 (0–4) 2 (0–4) 1 (1–3) 1 (0–3) 0.5 (0–3) 1 (0–2) 0 (0–0)#
HRQoL total 
score
2 (1–3) 2 (0–5) 3.5 (1–9) 7.5 (6–9) 8 (3–12) 4 (0–12) 5.5 (1–11) 3 (1–8) 0 (0–1)#
Pain/swell. 
in > 1 joint
3/6 (50%) 11/30 
(36.7%)
8/22 (36.4%) 2 (100%) 4/5 (80%) 7/11 
(63.6%)
8 (57.1%) 43/90 
(47.8%)
6 (6.1%)#
Morning 
stiffness 
> 15 min
0 (0%) 5/29 
(17.2%)
4/22 (18.2%) 2 (100%) 2/5 (40%) 2/11 
(18.2%)
6 (42.9%) 21/89 
(23.6%)**
2 (2%)#
Subjective 
remission
1/6 (16.7%) 12/30 (40%) 10/22 
(45.5%)
2 (100%) 2/4 (50%) 5/10 (50%) 6/12 (50%) 38/86 
(44.2%)
In treatment 5/5 (100%) 20/30 
(66.7%)
19/22 
(86.4%)
2 (100%) 4/4 (100%) 10/11 
(90.9%)
10/12 
(83.3%)
70/86 
(81.4%)
Reporting 
side effects
2/5 (40%) 2/20 (10%) 6/19 (31.6%) 1 (50%) 0 (0%) 5/10 (50%) 4/9 (44.4%) 20/69 (29%)
Taking 
medication 
regularly
4/5 (80%) 20/20 
(100%)
17/19 
(89.5%)
1 (50%) 4/4 (100%) 9/10 (90%) 9/10 (90%) 64/70 
(91.4%)
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Floor and ceiling effect
The median floor effect was 86.7% (80–92.2%) for the PF 
items, 55.6% (47.8–66.7%) for the HRQoL PhH items, and 
65.6% (64.4–70%) for the HRQoL PsH items. The median 
ceiling effect was 0% (0–1.1%) for the PF items, 4.4% 
(4.4–10%) for the HRQoL PhH items, and 0.0% (0–0%) for 
the HRQoL PsH items. The median floor effect was 38.9% 
for the pain VAS, 34.4% for the disease activity VAS and 
32.2% for the well-being VAS. The median ceiling effect 
was 0% for the pain VAS, 0% for the disease activity VAS 
and 0% for the well-being VAS.
Equal items‑scale correlations (second Likert 
assumption)
Pearson items-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the PF 
items, with the exception of items 11 and 15, and for 90% of 
the HRQoL items, with the exception of item 1.
Items internal consistency (third Likert assumption)
Pearson items-scale correlations were ≥ 0.4 for 93% of items 
of the PF (except for PF item 15) and 100% of items of the 
HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.86 for PF-LL, 0.89 for PF-HW, 0.74 
for PF-US. Cronbach’s alpha was 0.86 for HRQoL-PhH and 
0.76 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha, with 
the exception of Pf items 12, 13 and 14 and HRQoL item 3.
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.3 to 0.6 
(median = 0.4). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.6, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged from 
0.3 to 0.8 (median = 0.4), whereas for the PsH ranged from 
0.1 to 0.4 (median = 0.2). The PhH showed the best correla-
tion with the parent’s assessment of pain (r = 0.8, p < 0.001) 
and the PsH with the parent global assessment of well-being 
(r = 0.5, p < 0.001). The median correlations between the 
pain VAS, the well-being VAS, and the disease activity VAS 
and the physician-centred and laboratory measures were 0.3 
(0.1–0.4), 0.2 (0.1–0.3), 0.4 (0.2–0.5), respectively.
Discussion
In this study, the Flemish version of the JAMAR is the result 
of the local adaptation of the translation in Dutch performed 
by the PRINTO centre in the Netherlands. According to 
the results of the validation analysis, the Flemish parent 
and patient versions of the JAMAR possess satisfactory 
Data related to the JAMAR refers to the 90 JIA patients and to the 99 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05 **p < 0.001 #p < 0.0001
Table 1  (continued)
Systemic Oligoar-
thritis
RF− Poly-
arthritis
RF + Poly-
arthritis
Psoriatic 
arthritis
Enthesitis 
related 
arthritis
Undif-
ferentiated 
arthritis
All JIA 
patients
Healthy
N = 8 N = 33 N = 24 N = 2 N = 6 N = 13 N = 14 N = 100 N = 99
With 
problems 
attending 
school
0 (0%) 0 (0%) 0 (0%) 0 (0%) 2/3 (66.7%) 3/10 (30%) 0 (0%) 5/61 
(8.2%)**
1 (1.1%)*
Satisfied 
with 
disease 
outcome
6 (100%) 21 (77.8%) 16 (76.2%) 1 (50%) 3 (60%) 7 (63.6%) 7 (53.8%) 61 (71.8%)
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psychometric properties. The disease-specific components 
of the questionnaire discriminated well between patients 
with JIA and healthy controls.
Psychometric performances were good for all domains 
of the JAMAR with few exceptions: 1 PF item (“Bite into 
a sandwich or an apple”) showed a lower items internal 
consistency. However, the overall internal consistency was 
good for all the domains, with the exception of PF-US and 
HRQoL-PsH that were acceptable.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from week to moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents.
Test–retest reliability was not assessed in this patient 
sample.
The JAMAR is aimed to evaluate the side effects of 
medication and school attendance, which are other dimen-
sions of daily life that were not previously considered by 
other HRQoL tools. This may provide useful information 
for intervention and follow-up in health care. In conclusion, 
the Flemish version of the JAMAR was found to have satis-
factory psychometric properties and it is, thus, a reliable and 
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 90/189 Child N = 53/98
Missing values (1st–3rd quartiles) 1.1% (0.6–3.3%) 3.8% (1.9–5.7%)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 86.7% 90.6%
 HRQoL PhH 55.6% 60.4%
 HRQoL PsH 65.6% 73.6%
 Pain VAS 38.9% 34.0%
 Disease activity VAS 34.4% 28.3%
 Well-being VAS 32.2% 34.0%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 4.4% 1.9%
 HRQoL PsH 0.0% 0.0%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 0.0% 0.0%
Items with equivalent item-scale correlation 87% for PF, 90% for HRQoL 87% for PF, 80% for HRQoL
Items with items-scale correlation ≥ 0.4 93% for PF, 100% for HRQoL 80% for PF, 80% for HRQoL
Cronbach’s alpha
 PF-LL 0.86 0.81
 PF-HW 0.89 0.65
 PF-US 0.74 0.87
 HRQoL-PhH 0.86 0.81
 HRQoL-PsH 0.76 0.74
Items with item-scale correlation lower than the Cronbach alpha 80% for PF, 90% for HRQoL 100% for PF, 100% for HRQoL
Spearman correlation with JIA core-set variables, median
 PF 0.4 0.4
 HRQoL PhH 0.4 0.5
 HRQoL PsH 0.2 0.3
 Pain VAS 0.3 0.3
 Disease activity VAS 0.2 0.3
 Well-being VAS 0.4 0.4
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valid tool for the multidimensional assessment of children 
with JIA.
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